Statin use and reduced cancer-related mortality [1]

New England Journal of Medicine

Volumn 368, Issue 6, 2013, Pages 574-

  Corinne, Klop ^a   Driessen, Johanna H M ^b   De Vries, Frank ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PLACEBO;

CANCER MORTALITY; DRUG USE; FRACTURE; GENERAL PRACTITIONER; HUMAN; LETTER; NEOPLASM; OBSERVATIONAL STUDY; PNEUMONIA; PRESCRIPTION; PRIORITY JOURNAL; RISK FACTOR; SMOKING; FEMALE; MALE; MORTALITY; NOTE;

FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; NEOPLASMS;

EID: 84873507185     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1214827     Document Type: Letter

References (5)

1. Nielsen SF, Nordestgaard BG, Bojesen SE. Statin use and reduced cancer-related mortality. N Engl J Med 2012;367:1792-802.
2. Emberson JR, Kearney PM, Blackwell L, et al. Lack of effect of lowering LDL cholesterol on cancer: meta-analysis of individual data from 175,000 people in 27 randomised trials of statin therapy. PLoS One 2012;7(1):e29849.
3. de Vries F, de Vries C, Cooper C, Leufkens B, van Staa TP. Reanalysis of two studies with contrasting results on the association between statin use and fracture risk: the General Practice Research Database. Int J Epidemiol 2006;35:1301-8.
4. van de Garde EMW, Hak E, Souverein PC, Hoes AW, van den Bosch JM, Leufkens HG. Statin treatment and reduced risk of pneumonia in patients with diabetes. Thorax 2006;61:957-61.
5. Evans JS, Harries C, Dennis I, Dean J. General practitioners' tacit and stated policies in the prescription of lipid lowering agents. Br J Gen Pract 1995;45:15-8.